Ayanin
Based on 1 publication(s) in Google Scholar
Ayanin is a bioflavonoid isolated from Psychotria serpens. Ayanin is a non-selective phosphodiesterase1-4 inhibitor and can be used for the study of respiratory disease,such as allergic asthma et al.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 98.18%
- CAS 番号: 572-32-7
- 分子式: C18H16O7
- 分子量:344.32
-
保管条件:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
MedChemExpress(MCE)の使用を引用している文献 Ayanin
More
生物活性
|
PDE2A |
PDE4 |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| 2008 | IC50 |
50 μM
Compound: 16
|
Inhibition of MRP1 expressed in human 2008 cells assessed as calcein AM accumulation by cell based assay
Inhibition of MRP1 expressed in human 2008 cells assessed as calcein AM accumulation by cell based assay
|
[PMID: 21354800] |
| A2780 ADR | IC50 |
9.4 μM
Compound: 16
|
Inhibition of P-gp expressed in A2780adr cells by calcein AM accumulation assay
Inhibition of P-gp expressed in A2780adr cells by calcein AM accumulation assay
|
[PMID: 21354800] |
| A549 | IC50 |
20.79 μM
Compound: 6a
|
Anticancer activity against human A549 cells by HTS assay
Anticancer activity against human A549 cells by HTS assay
|
[PMID: 25139569] |
| BV-2 | IC50 |
25.1 μM
Compound: 95; 105
|
Anti-inflammatory activity in mouse BV-2 cells assessed as inhibition of LPS-induced NO production preincubated with compound for 1 hrs followed by LPS stimulation and measured after 24 hrs by Griess reagent based assay
Anti-inflammatory activity in mouse BV-2 cells assessed as inhibition of LPS-induced NO production preincubated with compound for 1 hrs followed by LPS stimulation and measured after 24 hrs by Griess reagent based assay
|
[PMID: 37683361] |
| Calu-1 | IC50 |
>50 μM
Compound: 6a
|
Anticancer activity against human Calu1 cells by HTS assay
Anticancer activity against human Calu1 cells by HTS assay
|
[PMID: 25139569] |
| HeLa | IC50 |
19.47 μM
Compound: 6a
|
Anticancer activity against human HeLa cells by HTS assay
Anticancer activity against human HeLa cells by HTS assay
|
[PMID: 25139569] |
| HEp-2 | IC50 |
6.1 μM
Compound: 16
|
Antiviral activity against RSV A2 infected in human HEp-2 cells assessed as reduction in viral plaque formation cells pretreated with compound for 15 mins followed by viral infection for 2.5 hrs and followed by incubation in CO2 incubator for 3 days by cr
Antiviral activity against RSV A2 infected in human HEp-2 cells assessed as reduction in viral plaque formation cells pretreated with compound for 15 mins followed by viral infection for 2.5 hrs and followed by incubation in CO2 incubator for 3 days by cr
|
[PMID: 36749598] |
| HOP-62 | IC50 |
20.06 μM
Compound: 6a
|
Anticancer activity against human HOP62 cells by HTS assay
Anticancer activity against human HOP62 cells by HTS assay
|
[PMID: 25139569] |
| J774.A1 | IC50 |
17.8 μM
Compound: 95; 105
|
Anti-inflammatory activity in mouse J774.A1 cells assessed as suppression of LPS-induced IL-6 production by ELISA analysis
Anti-inflammatory activity in mouse J774.A1 cells assessed as suppression of LPS-induced IL-6 production by ELISA analysis
|
[PMID: 37683361] |
| LOX IMVI | IC50 |
45.97 μM
Compound: 6a
|
Anticancer activity against human LOXIMVI cells by HTS assay
Anticancer activity against human LOXIMVI cells by HTS assay
|
[PMID: 25139569] |
| M14 | IC50 |
37.07 μM
Compound: 6a
|
Anticancer activity against human M14 cells by HTS assay
Anticancer activity against human M14 cells by HTS assay
|
[PMID: 25139569] |
| MCF7 | IC50 |
0.68 μM
Compound: 16
|
Inhibition of BCRP expressed in MCF-7 MX cells using Hoechst 33342 staining
Inhibition of BCRP expressed in MCF-7 MX cells using Hoechst 33342 staining
|
[PMID: 21354800] |
| MDCK | IC50 |
0.46 μM
Compound: 16
|
Inhibition of BCRP expressed in MDCK cells using Hoechst 33342 staining
Inhibition of BCRP expressed in MDCK cells using Hoechst 33342 staining
|
[PMID: 21354800] |
| MDCK | IC50 |
13 μM
Compound: 16
|
Inhibition of MDR1 expressed in MDCK cells using rhodamine 123 staining by flow cytometry
Inhibition of MDR1 expressed in MDCK cells using rhodamine 123 staining by flow cytometry
|
[PMID: 21354800] |
| NCI-H1299 | IC50 |
>50 μM
Compound: 6a
|
Anticancer activity against human H1299 cells by HTS assay
Anticancer activity against human H1299 cells by HTS assay
|
[PMID: 25139569] |
| NCI-H157 | IC50 |
18.64 μM
Compound: 6a
|
Anticancer activity against human NCI-H157 cells by HTS assay
Anticancer activity against human NCI-H157 cells by HTS assay
|
[PMID: 25139569] |
| NCI-H1792 | IC50 |
>50 μM
Compound: 6a
|
Anticancer activity against human NCI-H1792 cells by HTS assay
Anticancer activity against human NCI-H1792 cells by HTS assay
|
[PMID: 25139569] |
| NCI-H1944 | IC50 |
21.92 μM
Compound: 6a
|
Anticancer activity against human NCI-H1944 cells by HTS assay
Anticancer activity against human NCI-H1944 cells by HTS assay
|
[PMID: 25139569] |
| NCI-H460 | IC50 |
12.79 μM
Compound: 6a
|
Anticancer activity against human H460 cells by HTS assay
Anticancer activity against human H460 cells by HTS assay
|
[PMID: 25139569] |
| NCI-H460 | IC50 |
5.7 μM
Compound: 9
|
Inhibition of ABCG2 expressed in human NCI-H460 cells assessed as inhibition of PhA accumulation after 2 to 20 hrs relative to fumitremorgin C
Inhibition of ABCG2 expressed in human NCI-H460 cells assessed as inhibition of PhA accumulation after 2 to 20 hrs relative to fumitremorgin C
|
[PMID: 21275386] |
| NCI-H522 | IC50 |
20.21 μM
Compound: 6a
|
Anticancer activity against human NCI-H522 cells by HTS assay
Anticancer activity against human NCI-H522 cells by HTS assay
|
[PMID: 25139569] |
Ayanin inhibits interleukin (IL)-4 production from purified basophils with an IC50 value of 2.2 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
化学情報
-
CAS 番号 572-32-7
-
性状 Solid
-
分子量 344.32
-
分子式 C18H16O7
-
Color White to yellow
-
SMILES
O=C1C(OC)=C(C2=CC=C(OC)C(O)=C2)OC3=CC(OC)=CC(O)=C13
-
Structure Classification
-
Initial Source
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Nat Biomed Eng
DeepDrugDiscovery identifies blood-brain barrier permeable autophagy enhancers for Alzheimer's disease. [Abstract]2026 Apr 24. PMID: 42032039
溶剤 & 溶解度
DMSO : 250 mg/mL (726.07 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (6.04 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
純度とドキュメンテーション
-
データシート (273 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
取扱説明書 (2659 KB)
参考文献
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.9043 mL | 14.5214 mL | 29.0428 mL | 72.6069 mL |
| 5 mM | 0.5809 mL | 2.9043 mL | 5.8086 mL | 14.5214 mL | |
| 10 mM | 0.2904 mL | 1.4521 mL | 2.9043 mL | 7.2607 mL | |
| 15 mM | 0.1936 mL | 0.9681 mL | 1.9362 mL | 4.8405 mL | |
| 20 mM | 0.1452 mL | 0.7261 mL | 1.4521 mL | 3.6303 mL | |
| 25 mM | 0.1162 mL | 0.5809 mL | 1.1617 mL | 2.9043 mL | |
| 30 mM | 0.0968 mL | 0.4840 mL | 0.9681 mL | 2.4202 mL | |
| 40 mM | 0.0726 mL | 0.3630 mL | 0.7261 mL | 1.8152 mL | |
| 50 mM | 0.0581 mL | 0.2904 mL | 0.5809 mL | 1.4521 mL | |
| 60 mM | 0.0484 mL | 0.2420 mL | 0.4840 mL | 1.2101 mL | |
| 80 mM | 0.0363 mL | 0.1815 mL | 0.3630 mL | 0.9076 mL | |
| 100 mM | 0.0290 mL | 0.1452 mL | 0.2904 mL | 0.7261 mL |